Navigation Links
American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience
Date:9/16/2009

BETHESDA, Md., Sept. 16 /PRNewswire-FirstCall/ -- American Capital Ltd. (Nasdaq: ACAS) announced today that on September 15, it completed the sale of its portfolio company Axygen BioScience Inc., including its subsidiaries Axygen Inc. and Sorenson BioScience Inc., to Corning Incorporated for approximately $400 million. The total inception to date gain and income, including dividend and fee income, from the equity invested by American Capital's affiliated funds under management was $102 million, representing a 25% compounded annual rate of return. American Capital received $182 million in proceeds and realized a gain of $35 million from the transaction, subject to post-closing adjustments. American Capital's total inception to date realized gains on this investment were $36 million and its compounded annual rate of return, including interest and fees earned over the life of its investment was 22%. Including investments in Axygen BioScience by American Capital's affiliated funds under management, the inception to date realized gains were $61 million and the compounded annual rate of return was 22%. The proceeds received by American Capital were less than the second quarter 2009 valuation of the investment by $1 million, or less than 1%.

"Since the beginning of the fourth quarter of 2008, we've received approximately $875 million of proceeds from realizations of portfolio investment repayments and exits, including over 20 exits of portfolio companies," said Darin Winn, Senior Vice President and Senior Managing Director. "We are particularly pleased that all of our exits of control companies have been at enterprise multiples equal to or higher than our entry multiples."

Axygen BioScience is a leading manufacturer and distributor of high quality life sciences plastic consumables, liquid handling products and bench-top laboratory equipment.

"Over our three year investment in Axygen Bioscience, we have developed a great partnership with the management team and assisted in adding value to the company, enabling it to surpass its competition through growth and acquisitions," said Frank Do, Managing Director, Buyouts. "We are extremely proud of the company's improvements and success, which made it an attractive purchase for Corning Incorporated. The $35 million gain and 22% return on the Axygen Bioscience investment is an outstanding outcome for American Capital and its shareholders and a testament to our investment and exit strategies."

"The last few years have been exciting and rewarding for Axygen Bioscience and we are happy to have been a part of its success. The company successfully completed and integrated strategic acquisitions and partnerships, recorded robust financial performance and successfully launched new products," said Kimberly Reed, Principal, Buyouts. "We believe that moving forward, Corning's operational and financial support will enable Axygen Bioscience to secure a leading position in its industry."

American Capital invested in the One Stop Buyout(TM) of Axygen Inc. in September 2006. American Capital's investment took the form of a revolving credit facility, senior term loan, senior and junior subordinated debt and equity. In a series of transactions from November 2008 through March 2009, a new holding company, Axygen BioScience, was formed to include Axygen, Sorenson BioScience and Articles De Laboratoire De Precision (ALP). For more information about American Capital's original investment in Axygen, please go to http://www.americancapital.com/our_portfolio/companies/axygen.html.

Since American Capital's August 1997 IPO through the second quarter of 2009, the company has earned a 15% compounded annual return, including interest, dividends, fees and net gains, on 264 realizations of senior debt, subordinated debt and equity investments, totaling $12 billion of committed capital. These realizations represent 49% of all amounts invested by American Capital since its August 1997 IPO. Proceeds from these realizations exceeded the total associated prior quarter valuation of the investments by less than 1%. American Capital earned a 30% compounded annual return on the exit of its equity investments, including dividends, fees and net gains.

For a chart showing American Capital's exited portfolio companies, please go to http://www.americancapital.com/our_portfolio/exited.html.

ABOUT AMERICAN CAPITAL

American Capital is a publicly traded private equity firm and global asset manager. American Capital, both directly and through its asset management business, originates, underwrites and manages investments in middle market private equity, leveraged finance, real estate and structured products. Founded in 1986, American Capital has $11 billion(1) in capital resources under management and ten offices in the U.S., Europe and Asia. For further information, please refer to www.AmericanCapital.com.

(1) As of June 30, 2009.

Performance data quoted above represents past performance of American Capital. Past performance does not guarantee future results and the investment return and principal value of an investment in American Capital will likely fluctuate. Consequently, an investor's shares, when sold, may be worth more or less than their original cost. Additionally, American Capital's current performance may be lower or higher than the performance data quoted above.

This press release contains forward-looking statements. The statements regarding expected results of American Capital are subject to various factors and uncertainties, including the uncertainties associated with the timing of transaction closings, changes in interest rates, availability of transactions, changes in regional, national or international economic conditions or changes in the conditions of the industries in which American Capital has made investments.

    Contact:
    Frank Do, Managing Director, Buyouts - (310) 806-6280
    Kimberly Reed, Principal, Buyouts - (310) 806-6280
    Brian Martin, Vice President, Buyouts - (310) 806-6280
    Matthew Frankel, Vice President, Buyouts - (310) 806-6280
    Media - (301) 968-9400


'/>"/>
SOURCE American Capital Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
3. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
4. American Oriental Bioengineering Announces Participation in September Investor Conferences
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
7. Tips from the Journals of the American Society for Microbiology
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
10. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
11. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):